FDA warns Genovate over selling an unapproved HIV dried-blood-spot self-collection kit without marketing authorization.
What happened
FDA reviewed Genovate’s website, www.genovate.com, last visited in January 2026, and found the company offering an HIV dried blood spot card self-collection kit for delivery to individuals for self-collection and laboratory HIV testing. FDA said the kit has no approved premarket approval application (PMA) or investigational device exemption (IDE), and no required 510(k) notification was provided. FDA also said that after a March 31, 2025 letter, Genovate had not submitted any premarket submission for the kit.
What FDA found
Genovate offered an HIV self-collection kit for sale in the United States without FDA marketing authorization.
FD&C Act section 501(f)(1)(B), 21 U.S.C. 351(f)(1)(B)FDA says the kit is misbranded because Genovate did not notify FDA before introducing the device into commercial distribution as required by section 510(k).
FD&C Act section 502(o), 21 U.S.C. 352(o); section 510(k), 21 U.S.C. 360(k)The kit did not have an approved premarket approval application or an approved investigational device exemption.
FD&C Act section 515(a), 21 U.S.C. 360e(a); section 520(g), 21 U.S.C. 360j(g)
What FDA wants
FDA asks Genovate to immediately stop any activities that make the HIV DBS card self-collection kit misbranded or adulterated and to notify FDA in writing within 15 working days of the steps taken to correct the violations and prevent recurrence.
Who should pay attention
- makers of at-home diagnostic and self-collection kits
- laboratories that receive self-collected samples
- distributors and retailers selling HIV self-test kits
This is a summary. Read the original letter on fda.gov.